3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lung Neoplasms
2
Breast Neoplasms
2
Thymus Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Mesothelioma
1
Melanoma
1
Head and Neck Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Adenocarcinoma
1
Interventions
Bevacizumab
69
atezolizumab
54
lenvatinib
42
durvalumab
42
Nivolumab
38
pembrolizumab
35
tremelimumab
28
Magnetic Resonance Spectroscopy
21
Specimen Handling
19
tislelizumab
18
sintilimab
17
Ipilimumab
15
Sorafenib
14
regorafenib
13
cabozantinib
13
Radiosurgery
13
Radiotherapy
12
apatinib
11
Blood Specimen Collection
11
Immunoglobulin G
10
camrelizumab
9
Immune Checkpoint Inhibitors
9
Disulfides
9
X-Rays
8
Cyclophosphamide
8
donafenib
7
Oxaliplatin
7
Immunotherapy
7
Folfox protocol
7
Fluorouracil
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Histocompatibility Testing
×
1 year
×
Clear all
NCT07623265
2026-06-03
IO-MARC
Universitaire Ziekenhuizen KU Leuven
Phase NA
Recruiting
300 enrolled